Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
Int Surg ; 87(3): 185-90, 2002.
Article in English | MEDLINE | ID: mdl-12403096

ABSTRACT

Sixty-five patients with unresectable advanced epithelial ovarian cancer who underwent exploratory laparotomy or unilateral oophorectomy were reviewed. Forty-five of 65 patients received 3.8 cycles of neoadjuvant chemotherapy (NAC) and were successfully debulked at interval cytoreductive surgery (IRS); 31 of 45 showed no evidence of disease. Patients with residuals <1 cm at IRS had a high possibility of achieving clinical remission. Patients who failed to receive IRS showed poor prognosis. Also, 63 patients who underwent conventional primary debulking surgery with residuals >1 cm were investigated as a contrast. No significant difference was observed in patient survival between the NAC group and the conventional treatment group. NAC and IRS offered patients with unresectable tumors survival similar to that of those with suboptimally resectable tumors at primary debulking. We conclude that this strategy has potential benefits for the patients with clinically aggressive ovarian cancer who are unable to receive standard treatment.


Subject(s)
Carcinoma, Endometrioid/surgery , Ovarian Neoplasms/surgery , Ovariectomy , Aged , Antineoplastic Agents/therapeutic use , Carcinoma, Endometrioid/drug therapy , Carcinoma, Endometrioid/secondary , Chemotherapy, Adjuvant , Female , Humans , Ovarian Neoplasms/drug therapy , Ovarian Neoplasms/mortality , Ovarian Neoplasms/secondary , Retrospective Studies , Treatment Outcome
2.
Gan To Kagaku Ryoho ; 29(8): 1358-62, 2002 Aug.
Article in Japanese | MEDLINE | ID: mdl-12214461

ABSTRACT

We outline chemotherapy mainly for malignant ovarian germ cell and sex-cord tumors, based on studies in the literature and our own clinical experiences. With both tumors, PEB treatment is standard adjuvant chemotherapy. With regard to the number of dosage courses, 4 courses are regarded as tolerable after incomplete reduction, and 3 courses as adjuvant treatment after complete extraction. This chemotherapy is effective for preservation of fertility in young patients with malignant ovarian germ cell tumor. In both tumors, some cases show chemotherapy resistance. An effective second-line treatment strategy using a new anticancer agent needs to be established for such cases in the future.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Germinoma/drug therapy , Ovarian Neoplasms/drug therapy , Sex Cord-Gonadal Stromal Tumors/drug therapy , Adolescent , Adult , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Bleomycin/administration & dosage , Chemotherapy, Adjuvant , Child , Cisplatin/administration & dosage , Cyclophosphamide/administration & dosage , Dactinomycin/administration & dosage , Drug Administration Schedule , Etoposide/administration & dosage , Female , Germinoma/surgery , Humans , Ovarian Neoplasms/surgery , Sex Cord-Gonadal Stromal Tumors/surgery , Vinblastine/administration & dosage , Vincristine/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...